United Therapeutics Corporation (UTHR) /
The cash flow of United Therapeutics Corporation over the past 10 years
Chart United Therapeutics Corporation: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, United Therapeutics Corporation's operating cash flow was $1.56B and its capital expenditures $520.5M, leaving free cash flow of $1.04B. Free cash flow was above zero in 9 of the 10 years shown. It ranged from -$290.3M in fiscal 2019 to $1.08B in fiscal 2024. Capital expenditures were highest in fiscal 2025, at $520.5M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $1.56B | $520.5M | $1.04B |
| 2024ended Dec 31, 2024 | $1.33B | $246.5M | $1.08B |
| 2023ended Dec 31, 2023 | $978M | $230.4M | $747.6M |
| 2022ended Dec 31, 2022 | $802.5M | $138.8M | $663.7M |
| 2021ended Dec 31, 2021 | $598.2M | $120.8M | $477.4M |
| 2020ended Dec 31, 2020 | $755.7M | $59.3M | $696.4M |
| 2019ended Dec 31, 2019 | -$206.6M | $83.7M | -$290.3M |
| 2018ended Dec 31, 2018 | $778.4M | $184.4M | $594M |
| 2017ended Dec 31, 2017 | $474.2M | $86.3M | $387.9M |
| 2016ended Dec 31, 2016 | $643.6M | $38M | $605.6M |
Fiscal years as United Therapeutics Corporation reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on United Therapeutics Corporation
- The revenue of United Therapeutics Corporation
- The profitability of United Therapeutics Corporation
- The debt of United Therapeutics Corporation
- All of United Therapeutics Corporation's financials, charted
Companies of a similar size
- LHLABCORP HOLDINGS INC.
- ULTAULTA BEAUTY, INC.
- DGXQuest Diagnostics Inc
- DOVDOVER Corp
- CNPCENTERPOINT ENERGY INC
Not investment advice. This page shows what United Therapeutics Corporation filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.